Cargando…

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

Detalles Bibliográficos
Autores principales:	Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139920/ https://www.ncbi.nlm.nih.gov/pubmed/37131960 http://dx.doi.org/10.1016/j.jvacx.2023.100307

Ejemplares similares

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
por: Wolz, Olaf-Oliver, et al.
Publicado: (2022)

A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
por: Lenart, Klara, et al.
Publicado: (2022)

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
por: Kremsner, Peter G, et al.
Publicado: (2022)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
por: Ascaso-del-Rio, Ana, et al.
Publicado: (2022)

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
por: Kremsner, Peter G., et al.
Publicado: (2021)

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Hoffmann, Donata, et al.
Publicado: (2021)

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines
por: Moghimi, S. Moein
Publicado: (2021)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
por: Valentin, Antonio, et al.
Publicado: (2022)

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
por: Peng, Lei, et al.
Publicado: (2022)

New BVR photometry of six prominent RS CVn binaries
por: Padmakar, et al.
Publicado: (1999)

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
por: Somiya, Masaharu, et al.
Publicado: (2021)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
por: Moyles, Iain R., et al.
Publicado: (2023)

Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
por: Tsiambas, Evangelos, et al.
Publicado: (2021)

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
por: Zhang, Mengling, et al.
Publicado: (2020)

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
por: Granados-Riveron, Javier T., et al.
Publicado: (2021)

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
por: Zhang, Lizhou, et al.
Publicado: (2023)

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
por: Baldeon Vaca, Gabriela, et al.
Publicado: (2023)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
por: Patel, Nisarg, et al.
Publicado: (2023)

RS CVn vs. Algol-type binaries: a comparative study of their X-ray emission
por: Singh, K P, et al.
Publicado: (1996)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
por: Liu, Cong, et al.
Publicado: (2022)

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
por: Yu, Xiaojuan, et al.
Publicado: (2023)

mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
por: Bevers, Sanne, et al.
Publicado: (2022)

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2022)

Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery
por: Das, Riddha, et al.
Publicado: (2023)

The cvn8 Conservon System Is a Global Regulator of Specialized Metabolism in Streptomyces coelicolor during Interspecies Interactions
por: Bonet, Bailey, et al.
Publicado: (2021)

Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
por: Naderi Sohi, Alireza, et al.
Publicado: (2021)

A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium
por: Kon, Edo, et al.
Publicado: (2023)

A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice
por: He, Lihong, et al.
Publicado: (2022)

mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer
por: Qiu, Ke, et al.
Publicado: (2023)

Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR(7) Allosteric Agonist
por: Dickson, Louise, et al.
Publicado: (2023)

The effects of PEGylation on LNP based mRNA delivery to the eye
por: Ryals, Renee C., et al.
Publicado: (2020)

A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
por: Mao, Shanhong, et al.
Publicado: (2023)

Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2023)

2342. Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
por: England, Ross N, et al.
Publicado: (2023)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
por: Hermosilla, Jesús, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_beciebd12mcsh624qm3in1t9ei